Akero Therapeutics (AKRO) reported a Q4 loss Friday of $0.99, unchanged from a year earlier.
Two analysts polled by FactSet expected a loss of $1.19.
The company did not report any revenue for the quarter ended Dec. 31.
As of year-end, Akero had $797.8 million in cash, cash equivalents, and marketable securities that it expects to be sufficient for funding its current operating plan into 2028.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。